MedTrace Logo

Aprepitant for Prevention of Postoperative Nausea and Vomiting in Elective Hysterectomy

NCT00888329 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 256

Last updated 2012-03-30

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine whether 40 mg aprepitant administered before surgery is effective for preventing vomiting in the first 24 hours after surgery in women undergoing elective hysterectomy.

Conditions

  • Postoperative Nausea and Vomiting

Interventions

DRUG

Aprepitant

40 mg administered orally with a sip of water prior to anesthesia induction.

DRUG

Placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • Javier Magrina, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00888329 on ClinicalTrials.gov